Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03228667
Title QUILT-3.055: A Phase IIb, Single-Arm, Open-Label Study of ALT-803 in Combination With Pembrolizumab or Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Disease Progression Following an Initial Response to Treatment With PD-1 Checkpoint Inhibitor Therapy
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Altor Bioscience Corporation
Indications

lung non-small cell carcinoma

Therapies

ALT-803 + Nivolumab

ALT-803 + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.